Cancer Genetics Stock Price, News & Analysis (NASDAQ:CGIX)

$1.80 0.00 (0.00 %)
(As of 02/21/2018 12:24 PM ET)
Previous Close$1.80
Today's Range$1.75 - $1.80
52-Week Range$1.55 - $5.30
Volume19,700 shs
Average Volume140,541 shs
Market Capitalization$49.87 million
P/E Ratio-1.86
Dividend YieldN/A
Beta1.14

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics logoCancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.

Receive CGIX News and Ratings via Email

Sign-up to receive the latest news and ratings for CGIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Healthcare Facilities & Services
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGIX
CUSIPN/A
Phone201-528-9200

Debt

Debt-to-Equity Ratio0.18%
Current Ratio2.01%
Quick Ratio2.01%

Price-To-Earnings

Trailing P/E Ratio-1.85565097267038
Forward P/E Ratio-2.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.05 million
Price / Sales1.84
Cash FlowN/A
Price / CashN/A
Book Value$1.36 per share
Price / Book1.32

Profitability

Trailing EPS($0.97)
Net Income$-15,800,000.00
Net Margins-54.65%
Return on Equity-46.21%
Return on Assets-24.62%

Miscellaneous

Employees155
Outstanding Shares27,700,000

Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How were Cancer Genetics' earnings last quarter?

Cancer Genetics Inc (NASDAQ:CGIX) announced its earnings results on Thursday, May, 11th. The medical research company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. The medical research company had revenue of $7 million for the quarter, compared to the consensus estimate of $7.62 million. Cancer Genetics had a negative return on equity of 46.21% and a negative net margin of 54.65%. The company's revenue was up 14.8% on a year-over-year basis. During the same period last year, the business posted ($0.39) EPS. View Cancer Genetics' Earnings History.

Where is Cancer Genetics' stock going? Where will Cancer Genetics' stock price be in 2018?

4 brokerages have issued 1-year price objectives for Cancer Genetics' shares. Their predictions range from $6.00 to $6.00. On average, they expect Cancer Genetics' share price to reach $6.00 in the next twelve months. View Analyst Ratings for Cancer Genetics.

What are Wall Street analysts saying about Cancer Genetics stock?

Here are some recent quotes from research analysts about Cancer Genetics stock:

  • 1. Maxim Group analysts commented, "As the paradigm in oncology shifts to immune therapy with CAR-T, PARPs, Checkpoints, and even BTK inhibitors attracting attention, we must not forget that it is the advances in diagnostics/theranostics and molecular profiling that enable guided therapy." (12/7/2017)
  • 2. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (11/29/2017)

Are investors shorting Cancer Genetics?

Cancer Genetics saw a decrease in short interest during the month of January. As of January 12th, there was short interest totalling 519,860 shares, a decrease of 26.7% from the December 29th total of 708,949 shares. Based on an average daily trading volume, of 155,028 shares, the short-interest ratio is presently 3.4 days. Currently, 2.3% of the shares of the company are short sold.

Who are some of Cancer Genetics' key competitors?

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the folowing people:

  • John A. Roberts, Interim Chief Executive Officer, Chief Financial Officer, Principal Financial Officer (Age 58)
  • Igor Gitelman CPA, Chief Accounting Officer, Principal Accounting Officer (Age 41)
  • Rita Shaknovich, Medical Director, Vice President - Hematopathology Services (Age 50)
  • Jane Houldsworth Ph.D., Vice President - Research & Development (Age 57)
  • John G. Pappajohn, Non-Executive Chairman of the Board (Age 88)
  • Raju S. K. Chaganti Ph.D., Director (Age 83)
  • Geoffrey Eric Harris, Director (Age 54)
  • Thomas F. Widmann M.D., Director (Age 69)
  • Edmund M. Cannon, Independent Director (Age 72)

Who owns Cancer Genetics stock?

Cancer Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (6.45%), STONEPINE CAPITAL MANAGEMENT, LLC (5.00%), Perkins Capital Management Inc. (3.57%), Renaissance Technologies LLC (1.88%) and Two Sigma Securities LLC (0.24%). Company insiders that own Cancer Genetics stock include Edward J Sitar, Geoffrey E Harris, Igor Gitelman, John A Roberts, John Pappajohn and Panna Sharma. View Institutional Ownership Trends for Cancer Genetics.

Who sold Cancer Genetics stock? Who is selling Cancer Genetics stock?

Cancer Genetics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Cancer Genetics.

Who bought Cancer Genetics stock? Who is buying Cancer Genetics stock?

Cancer Genetics' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Perkins Capital Management Inc. and Two Sigma Securities LLC. Company insiders that have bought Cancer Genetics stock in the last two years include Geoffrey E Harris, Igor Gitelman, John A Roberts, John Pappajohn and Panna Sharma. View Insider Buying and Selling for Cancer Genetics.

How do I buy Cancer Genetics stock?

Shares of Cancer Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cancer Genetics' stock price today?

One share of Cancer Genetics stock can currently be purchased for approximately $1.80.

How big of a company is Cancer Genetics?

Cancer Genetics has a market capitalization of $49.87 million and generates $27.05 million in revenue each year. The medical research company earns $-15,800,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Cancer Genetics employs 155 workers across the globe.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]


MarketBeat Community Rating for Cancer Genetics (CGIX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  246
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cancer Genetics (NASDAQ:CGIX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.672.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$6.00$6.00
Price Target Upside: 233.33% upside200.00% upside110.53% upside53.85% upside

Cancer Genetics (NASDAQ:CGIX) Consensus Price Target History

Price Target History for Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics (NASDAQ:CGIX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/6/2018HC WainwrightSet Price TargetBuy$6.00LowView Rating Details
12/13/2017Maxim GroupSet Price TargetBuy$6.00MediumView Rating Details
6/27/2017Dawson JamesInitiated CoverageBuyHighView Rating Details
6/26/2017BenchmarkInitiated CoverageSpeculative Buy$3.85 -> $6.00HighView Rating Details
9/26/2016Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
3/15/2016AegisBoost Price TargetBuy$8.00 -> $15.00N/AView Rating Details
3/11/2016Janney Montgomery ScottReiterated RatingBuy -> NeutralN/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Cancer Genetics (NASDAQ:CGIX) Earnings History and Estimates Chart

Earnings by Quarter for Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics (NASDAQ CGIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.13)($0.16)$7.96 million$8.03 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.16)($0.16)$7.97 million$6.60 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.18)($0.11)$7.62 million$7.00 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.22)($0.15)$7.10 million$7.23 millionViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)$6.93 million$6.80 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.28)$6.50 million$7.00 millionViewN/AView Earnings Details
5/10/2016Q1($0.43)($0.39)$6.95 million$6.10 millionViewListenView Earnings Details
3/10/2016Q415($0.46)($0.48)$7.00 million$5.50 millionViewListenView Earnings Details
11/10/2015Q315($0.49)($0.56)$5.13 million$4.00 millionViewListenView Earnings Details
8/11/2015Q215($0.50)($0.51)$4.67 million$4.20 millionViewListenView Earnings Details
5/12/2015Q115($0.54)($0.43)$3.91 million$4.40 millionViewListenView Earnings Details
3/12/2015Q414($0.52)($0.49)$3.70 million$4.00 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.51)($0.41)$3.11 million$3.22 millionViewN/AView Earnings Details
8/14/2014Q214($0.39)($0.50)$2.13 million$3.20 millionViewN/AView Earnings Details
5/15/2014Q114($0.29)($0.27)$2.17 million$1.40 millionViewN/AView Earnings Details
3/26/2014Q4 13($0.36)($0.37)$1.95 million$1.90 millionViewN/AView Earnings Details
11/13/2013Q313($0.71)($0.61)$1.60 million$1.70 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.53)($0.57)$1.50 million$1.83 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cancer Genetics (NASDAQ:CGIX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.82 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS

Dividends

Dividend History for Cancer Genetics (NASDAQ:CGIX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cancer Genetics (NASDAQ CGIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.30%
Institutional Ownership Percentage: 17.90%
Insider Trades by Quarter for Cancer Genetics (NASDAQ:CGIX)
Institutional Ownership by Quarter for Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics (NASDAQ CGIX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017John A RobertsCOOBuy12,200$2.00$24,400.0012,200View SEC Filing  
12/8/2017John PappajohnDirectorBuy150,000$1.86$279,000.002,781,204View SEC Filing  
8/18/2017John PappajohnDirectorBuy86,185$3.24$279,239.402,608,704View SEC Filing  
8/17/2017John PappajohnDirectorBuy86,185$3.24$279,239.402,608,704View SEC Filing  
6/12/2017John PappajohnDirectorBuy100,000$3.75$375,000.002,542,519View SEC Filing  
5/25/2017Igor GitelmanInsiderBuy937$3.95$3,701.15937View SEC Filing  
5/23/2017Igor GitelmanInsiderSell937$4.02$3,766.74937View SEC Filing  
5/16/2017Geoffrey E HarrisDirectorBuy2,500$3.75$9,375.0022,500View SEC Filing  
12/14/2016Geoffrey E HarrisDirectorBuy2,500$1.50$3,750.0020,000View SEC Filing  
11/28/2016John PappajohnDirectorBuy100,000$1.45$145,000.002,420,709View SEC Filing  
11/16/2016Edward J SitarCFOSell3,333$1.56$5,199.4814,167View SEC Filing  
11/14/2016John PappajohnDirectorBuy31,100$1.48$46,028.002,320,709View SEC Filing  
8/16/2016John PappajohnDirectorBuy45,000$2.29$103,050.002,287,109View SEC Filing  
8/15/2016John PappajohnDirectorBuy147,500$2.16$318,600.002,162,387View SEC Filing  
3/17/2016John PappajohnDirectorBuy50,000$2.64$132,000.001,771,789View SEC Filing  
3/17/2016Panna SharmaCEOBuy1,500$2.59$3,885.00152,000View SEC Filing  
3/16/2016John PappajohnDirectorBuy100,000$2.53$253,000.001,711,210View SEC Filing  
3/15/2016Panna SharmaCEOBuy1,000$2.56$2,560.00151,000View SEC Filing  
8/27/2015John PappajohnDirectorBuy5,000$9.61$48,050.001,519,289View SEC Filing  
6/25/2015Raju S.K. ChagantiDirectorSell5,296$12.00$63,552.00View SEC Filing  
6/12/2015Raju S.K. ChagantiDirectorSell7,000$12.01$84,070.00View SEC Filing  
6/11/2015Raju S.K. ChagantiDirectorSell46,454$12.03$558,841.62View SEC Filing  
6/8/2015Raju S.K. ChagantiDirectorSell24,583$12.03$295,733.49View SEC Filing  
5/14/2015John PappajohnDirectorBuy5,000$10.74$53,700.00View SEC Filing  
3/17/2015John PappajohnDirectorBuy50,000$7.36$368,000.00View SEC Filing  
3/16/2015Edward J SitarCFOBuy1,000$6.99$6,990.00View SEC Filing  
12/16/2014John PappajohnDirectorBuy5,589$6.20$34,651.80View SEC Filing  
12/15/2014John PappajohnDirectorBuy3,634$6.14$22,312.76View SEC Filing  
12/11/2014John PappajohnDirectorBuy27,087$6.03$163,334.61View SEC Filing  
12/10/2014John PappajohnDirectorBuy5,773$5.96$34,407.08View SEC Filing  
12/9/2014John PappajohnDirectorBuy39,686$5.35$212,320.10View SEC Filing  
5/21/2014Edward SitarCFOBuy1,000$10.67$10,670.001,000View SEC Filing  
5/21/2014John PappajohnDirectorBuy50,000$10.31$515,500.001,313,232View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cancer Genetics (NASDAQ CGIX) News Headlines

Source:
DateHeadline
$9.45 Million in Sales Expected for Cancer Genetics Inc (CGIX) This Quarter$9.45 Million in Sales Expected for Cancer Genetics Inc (CGIX) This Quarter
www.americanbankingnews.com - February 21 at 4:32 AM
Cancer Genetics Inc (CGIX) Receives Average Rating of "Hold" from BrokeragesCancer Genetics Inc (CGIX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 20 at 2:34 PM
Zacks: Brokerages Anticipate Cancer Genetics Inc (CGIX) Will Announce Earnings of -$0.11 Per ShareZacks: Brokerages Anticipate Cancer Genetics Inc (CGIX) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - February 19 at 1:16 PM
Cancer Genetics (CGIX) Given a $6.00 Price Target by HC Wainwright AnalystsCancer Genetics (CGIX) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - February 6 at 12:12 PM
Cancer Genetics Inc (CGIX) Expected to Announce Quarterly Sales of $9.45 MillionCancer Genetics Inc (CGIX) Expected to Announce Quarterly Sales of $9.45 Million
www.americanbankingnews.com - February 4 at 4:18 AM
Cancer Genetics Inc Forecasted to Earn FY2017 Earnings of ($0.75) Per Share (CGIX)Cancer Genetics Inc Forecasted to Earn FY2017 Earnings of ($0.75) Per Share (CGIX)
www.americanbankingnews.com - January 31 at 8:02 AM
Cancer Genetics Inc (CGIX) Sees Large Decrease in Short InterestCancer Genetics Inc (CGIX) Sees Large Decrease in Short Interest
www.americanbankingnews.com - January 29 at 1:20 AM
Cancer Genetics Inc (CGIX) Receives Consensus Rating of "Hold" from BrokeragesCancer Genetics Inc (CGIX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 26 at 8:44 AM
Reviewing Select Medical (SEM) and Cancer Genetics (CGIX)Reviewing Select Medical (SEM) and Cancer Genetics (CGIX)
www.americanbankingnews.com - January 25 at 3:12 AM
Cancer Genetics Expands Its Industry-Leading Immuno-Oncology Panel, Complete::IO™, to be the Most Comprehensive for Immune Profiling & MonitoringCancer Genetics Expands Its Industry-Leading Immuno-Oncology Panel, Complete::IO™, to be the Most Comprehensive for Immune Profiling & Monitoring
finance.yahoo.com - January 17 at 9:13 AM
Analyzing Select Medical (SEM) and Cancer Genetics (CGIX)Analyzing Select Medical (SEM) and Cancer Genetics (CGIX)
www.americanbankingnews.com - January 10 at 9:46 AM
Cancer Genetics Inc (CGIX) Receives Consensus Rating of "Hold" from AnalystsCancer Genetics Inc (CGIX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 1 at 7:28 AM
Zacks: Brokerages Expect Cancer Genetics Inc (CGIX) Will Post Earnings of -$0.10 Per ShareZacks: Brokerages Expect Cancer Genetics Inc (CGIX) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - December 30 at 7:08 PM
Cancer Genetics Receives Non-Dilutive Funding of $1.1 Million through New Jersey Technology Business Tax Certificate Transfer (NOL) ProgramCancer Genetics Receives Non-Dilutive Funding of $1.1 Million through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
finance.yahoo.com - December 28 at 8:59 AM
Financial Analysis: Cancer Genetics (CGIX) vs. The Providence Service (PRSC)Financial Analysis: Cancer Genetics (CGIX) vs. The Providence Service (PRSC)
www.americanbankingnews.com - December 22 at 3:04 AM
Cancer Genetics Receives New York State Approval for FDA-Approved Oncomine Dx Target Test by Thermo Fisher ScientificCancer Genetics Receives New York State Approval for FDA-Approved Oncomine Dx Target Test by Thermo Fisher Scientific
finance.yahoo.com - December 19 at 9:26 AM
ETFs with exposure to Cancer Genetics, Inc. : December 18, 2017ETFs with exposure to Cancer Genetics, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 5:23 PM
Cancer Genetics, Inc. :CGIX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017Cancer Genetics, Inc. :CGIX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017
finance.yahoo.com - December 18 at 5:23 PM
John A. Roberts Acquires 12,200 Shares of Cancer Genetics Inc (CGIX) StockJohn A. Roberts Acquires 12,200 Shares of Cancer Genetics Inc (CGIX) Stock
www.americanbankingnews.com - December 18 at 8:36 AM
Cancer Genetics (CGIX) vs. Davita (DVA) Head to Head ContrastCancer Genetics (CGIX) vs. Davita (DVA) Head to Head Contrast
www.americanbankingnews.com - December 17 at 5:34 PM
Cancer Genetics (CGIX) Given a $6.00 Price Target by Maxim Group AnalystsCancer Genetics (CGIX) Given a $6.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - December 17 at 3:46 PM
Zacks: Brokerages Expect Cancer Genetics Inc (CGIX) Will Announce Earnings of -$0.10 Per ShareZacks: Brokerages Expect Cancer Genetics Inc (CGIX) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - December 13 at 5:36 PM
Cancer Genetics Inc (CGIX) Director Purchases $279,000.00 in StockCancer Genetics Inc (CGIX) Director Purchases $279,000.00 in Stock
www.americanbankingnews.com - December 11 at 5:38 PM
Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 ... - GlobeNewswire (press release)Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 ... - GlobeNewswire (press release)
globenewswire.com - December 11 at 10:09 AM
Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 expression analysis with RNA analysisCancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 expression analysis with RNA analysis
finance.yahoo.com - December 11 at 10:09 AM
Cancer Genetics Prices $7 Million Registered Direct OfferingCancer Genetics Prices $7 Million Registered Direct Offering
finance.yahoo.com - December 8 at 9:24 AM
Cancer Genetics Inc (CGIX) Given Consensus Rating of "Hold" by AnalystsCancer Genetics Inc (CGIX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 7 at 10:26 AM
Maxim Group Reaffirms "Buy" Rating for Cancer Genetics (CGIX)Maxim Group Reaffirms "Buy" Rating for Cancer Genetics (CGIX)
www.americanbankingnews.com - December 7 at 8:34 AM
ETFs with exposure to Cancer Genetics, Inc. : December 5, 2017ETFs with exposure to Cancer Genetics, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 5:20 PM
ValuEngine Lowers Cancer Genetics (CGIX) to Strong SellValuEngine Lowers Cancer Genetics (CGIX) to Strong Sell
www.americanbankingnews.com - December 3 at 7:58 PM
Cancer Genetics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)Cancer Genetics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - November 30 at 9:55 AM
Cancer Genetics to Participate in Upcoming Investor ConferencesCancer Genetics to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 30 at 9:55 AM
Cancer Genetics (CGIX) Upgraded at Zacks Investment ResearchCancer Genetics (CGIX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 29 at 6:04 PM
HC Wainwright Analysts Give Cancer Genetics (CGIX) a $6.00 Price TargetHC Wainwright Analysts Give Cancer Genetics (CGIX) a $6.00 Price Target
www.americanbankingnews.com - November 29 at 12:22 PM
Cancer Genetics (CGIX) Appoints Thomas Widmann to its Board of Directors - StreetInsider.comCancer Genetics (CGIX) Appoints Thomas Widmann to its Board of Directors - StreetInsider.com
www.streetinsider.com - November 29 at 9:27 AM
Cancer Genetics Initiates Partnership to Reduce Alarmingly Increasing Cancer Mortality Rates in India - GlobeNewswire (press release)Cancer Genetics Initiates Partnership to Reduce Alarmingly Increasing Cancer Mortality Rates in India - GlobeNewswire (press release)
globenewswire.com - November 29 at 9:27 AM
Cancer Genetics and Indian Cooperative Oncology Network (ICON) Collaborate to Reduce Alarmingly Increasing Cancer Mortality RatesCancer Genetics and Indian Cooperative Oncology Network (ICON) Collaborate to Reduce Alarmingly Increasing Cancer Mortality Rates
finance.yahoo.com - November 29 at 9:27 AM
Cancer Genetics Initiates Partnership to Reduce Alarmingly Increasing Cancer Mortality Rates in IndiaCancer Genetics Initiates Partnership to Reduce Alarmingly Increasing Cancer Mortality Rates in India
finance.yahoo.com - November 29 at 9:27 AM
Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of DirectorsCancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors
finance.yahoo.com - November 27 at 6:19 PM
Cancer Genetics, Inc. (CGIX) Expected to Post Quarterly Sales of $9.45 MillionCancer Genetics, Inc. (CGIX) Expected to Post Quarterly Sales of $9.45 Million
www.americanbankingnews.com - November 27 at 6:20 AM
Cancer Genetics (CGIX) versus The Providence Service (PRSC) Financial AnalysisCancer Genetics (CGIX) versus The Providence Service (PRSC) Financial Analysis
www.americanbankingnews.com - November 26 at 5:10 AM
Zacks: Analysts Expect Cancer Genetics, Inc. (CGIX) Will Announce Earnings of -$0.10 Per ShareZacks: Analysts Expect Cancer Genetics, Inc. (CGIX) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - November 25 at 9:16 PM
Cancer Genetics (CGIX) CEO Panna Sharma on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaCancer Genetics' (CGIX) CEO Panna Sharma on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 11 at 10:01 PM
ETFs with exposure to Cancer Genetics, Inc. : November 10, 2017ETFs with exposure to Cancer Genetics, Inc. : November 10, 2017
finance.yahoo.com - November 10 at 4:53 PM
Form 8-K CANCER GENETICS, INC For: Nov 09 - StreetInsider.com - StreetInsider.comForm 8-K CANCER GENETICS, INC For: Nov 09 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - November 10 at 10:03 AM
Cancer Genetics to Present Insights to Advance Precision Medicine in Non-Small Cell Lung Cancer (NSCLC) at AMP ... - GlobeNewswire (press release)Cancer Genetics to Present Insights to Advance Precision Medicine in Non-Small Cell Lung Cancer (NSCLC) at AMP ... - GlobeNewswire (press release)
globenewswire.com - November 10 at 10:03 AM
Edited Transcript of CGIX earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of CGIX earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 10 at 10:03 AM
Cancer Genetics, Inc. to Host Earnings CallCancer Genetics, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 8:01 PM
Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical CompaniesCancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies
finance.yahoo.com - November 9 at 8:01 PM
Cancer Genetics reports 3Q lossCancer Genetics reports 3Q loss
finance.yahoo.com - November 9 at 8:01 PM

SEC Filings

Cancer Genetics (NASDAQ:CGIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cancer Genetics (NASDAQ:CGIX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cancer Genetics (NASDAQ CGIX) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.